These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14639347)

  • 21. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines.
    Radvanyi L
    Int Arch Allergy Immunol; 2004 Feb; 133(2):179-97. PubMed ID: 14764946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poxvirus-based vectors as vaccine candidates.
    Pincus S; Tartaglia J; Paoletti E
    Biologicals; 1995 Jun; 23(2):159-64. PubMed ID: 7546658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular Mucins: Targets for Immunotherapy.
    Apostolopoulos V; McKenzie IFC
    Crit Rev Immunol; 2017; 37(2-6):421-437. PubMed ID: 29773028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic glycopeptides for the development of cancer vaccines.
    Liakatos A; Kunz H
    Curr Opin Mol Ther; 2007 Feb; 9(1):35-44. PubMed ID: 17330400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer vaccines: the state of the art.
    Finn OO; Banchereau J
    Semin Immunol; 2010 Jun; 22(3):103-4. PubMed ID: 20552730
    [No Abstract]   [Full Text] [Related]  

  • 27. Listeria monocytogenes and its products as agents for cancer immunotherapy.
    Guirnalda P; Wood L; Paterson Y
    Adv Immunol; 2012; 113():81-118. PubMed ID: 22244580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live-attenuated bacteria as a cancer vaccine vector.
    Toussaint B; Chauchet X; Wang Y; Polack B; Le Gouëllec A
    Expert Rev Vaccines; 2013 Oct; 12(10):1139-54. PubMed ID: 24124876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
    Vormehr M; Schrörs B; Boegel S; Löwer M; Türeci Ö; Sahin U
    J Immunol Res; 2015; 2015():595363. PubMed ID: 26844233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical development of MVA-based therapeutic cancer vaccines.
    Acres B; Bonnefoy JY
    Expert Rev Vaccines; 2008 Sep; 7(7):889-93. PubMed ID: 18767940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
    Schlom J; Palena C; Greiner JW; Tsang KY; Grosenbach DW; Sabzevari H; Gulley JL; Arlen PM; Kass E; Hodge JW
    Dev Biol (Basel); 2004; 116():27-47. PubMed ID: 15603182
    [No Abstract]   [Full Text] [Related]  

  • 33. Integrating a 'danger' signal into molecular chaperoning to improve vaccination against cancer.
    Yu X; Subjeck JR; Wang XY
    Expert Rev Vaccines; 2013 Jun; 12(6):581-3. PubMed ID: 23750787
    [No Abstract]   [Full Text] [Related]  

  • 34. [NY-ESO-1 and cancer immunotherapy].
    Peng JR; Leng XS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokines, tumour-cell death and immunogenicity: a question of choice.
    Musiani P; Modesti A; Giovarelli M; Cavallo F; Colombo MP; Lollini PL; Forni G
    Immunol Today; 1997 Jan; 18(1):32-6. PubMed ID: 9018972
    [No Abstract]   [Full Text] [Related]  

  • 36. Live-attenuated Listeria-based immunotherapy.
    Rothman J; Paterson Y
    Expert Rev Vaccines; 2013 May; 12(5):493-504. PubMed ID: 23659298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The next generation of vaccines for the treatment of cancer.
    Long L; Glover RT; Kaufman HL
    Curr Opin Mol Ther; 1999 Feb; 1(1):57-63. PubMed ID: 11249685
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunologic basis of vaccine vectors.
    Liu MA
    Immunity; 2010 Oct; 33(4):504-15. PubMed ID: 21029961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-replicating expression vectors: applications in vaccine development and gene therapy.
    Limbach KJ; Paoletti E
    Epidemiol Infect; 1996 Jun; 116(3):241-56. PubMed ID: 8666067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease.
    Weiskirch LM; Paterson Y
    Immunol Rev; 1997 Aug; 158():159-69. PubMed ID: 9314084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.